Official-source baseline for Aardvark Therapeutics using SEC submissions, SEC XBRL companyfacts, FY2025 10-K, Q1 FY2026 10-Q, company-filed results releases, clinical-update 8-Ks, prospectus filings, and peer filings.
References
Sources used in this report
SEC submissionsSEC submissions JSON for CIK 00017748572026-05-13 · Issuer identity, ticker, exchange, SIC, fiscal year end, address metadata, and filing inventory.SEC companyfactsSEC XBRL companyfacts for CIK 00017748572026-05-13 · Structured financial facts used as cross-check.Annual reportAardvark FY2025 Form 10-K2026-03-23 · Business model, pipeline, no-revenue disclosure, FY2025 financials, cash runway, employees, IP, manufacturing, competition, governance, and risks.Company earnings releaseAardvark FY2025 results release, Exhibit 99.12026-03-23 · Management update on voluntary pauses, ARD-101 cardiac observations, ARD-201, publication summary, FY2025 cash runway, R&D, G&A, and net loss.Company clinical updateAardvark February 27, 2026 HERO pause update, Exhibit 99.12026-02-27 · Initial voluntary pause disclosure for HERO and OLE.Company clinical updateAardvark February 10, 2026 HERO protocol update, Exhibit 99.12026-02-10 · Pre-pause trial design, eligibility expansion, and HERO context.Quarterly reportAardvark Q1 FY2026 Form 10-Q2026-05-07 · Latest financial statements, cash, burn, risk updates, ATM status, and pause status.Company earnings releaseAardvark Q1 FY2026 results release, Exhibit 99.12026-05-07 · Latest management update, runway into mid-2027, and Q1 financial highlights.Company presentationAardvark January 2026 company presentation, Exhibit 99.12026-01-12 · Pipeline, mechanism, and pre-pause company strategy, used with caution because it predates the pause.Prospectus supplementAardvark 424B5 prospectus supplement2026-04-03 · Shelf/ATM context and dilution risk.Final prospectusAardvark IPO prospectus2025-02-13 · IPO and company-stage context.Competitor quarterly reportSoleno Therapeutics Q1 FY2026 Form 10-Q2026-05-07 · Official PWS hyperphagia peer context.Competitor quarterly reportRhythm Pharmaceuticals Q1 FY2026 Form 10-Q2026-05-05 · Official rare metabolic disease and obesity-treatment peer context.Competitor quarterly reportRelmada Therapeutics Q1 FY2026 Form 10-Q2026-05-12 · Official clinical-stage biotech peer context.Competitor annual reportBright Minds Biosciences FY2025 Form 40-F2025-12-23 · Official clinical-stage biotechnology peer context.